Positive News for Triple Negative

Worldwide, one in eight women are affected by breast cancer affects during their lives.1 While there are many risk factors, it is not known why some women get breast cancer and others do not.1 It is the second most common form of cancer, after skin cancer.2 Based on 2013-2015 data from the NIH based on US populations, approximately 12.4 percent of women will be diagnosed with female breast cancer at some point during their lifetime. 3 One of the most problematic of these, from the standpoint of treatment, is triple negative breast cancer (TNBC). This is because the cancer cells do not contain receptors for estrogen, progesterone, or HER2, and therefore these hormones do not fuel their growth.  It is usually invasive and typically originates in the breast ducts. Since it does not contain these receptors, it is not responsive to hormone therapies. The incident rates for this type accounts for approximately 10-20% of all breast cancers.4


Now, the researchers at Princeton University, led by the senior author Dr Yibin Kang, have identified a protein, Tinagl1(Tubulointerstitial nephritis antigen-like 1), that has been shown to suppress the TNBCprogress and metastasis by binding integrin α5β1, αvβ1, and epidermal growth factor receptor (EGFR), and subsequent contemporaneous inhibition of focal adhesion kinase (FAK) and EGFR signaling pathways. Their results, from a mouse study and published in Cancer Cell,5 found that Tinagl1 inhibited two of the main pathways that contribute to triple-negative breast cancer's aggressiveness and ability to resist treatments. Tinagl1 inhibited both of these pathways in distinguishable ways, defeating the countervailing mechanisms that the cancer uses to evade treatments. 5 The dual inhibition of integrin/FAK and EGFR signaling pathways lends itself to a potential therapeutic agent.

Peptides International offers TINAGL1 Human and TINAGL1 Human, Sf9.


  1. https://medlineplus.gov/breastcancer.html  
  2. https://www.cancer.gov/types/breast
  3. https://seer.cancer.gov/statfacts/html/breast.html
  4. https://www.breastcancer.org/symptoms/diagnosis/trip_neg
  5. https://doi.org/10.1016/j.ccell.2018.11.016 and https://www.drugtargetreview.com/news/38580/breast-cancer-treatment
Industry News , Recombinant Proteins , Cancer

Robert Brousseau

See all articles from Robert Brousseau

Robert Brousseau, the Director of Marketing and Catalog Sales Development at Peptides International, has a wide range of responsibilities that include maintaining the Peptides International brand integrity and creating and implementing all materials related to marketing the company's product line. He is also tasked with the catalog portfolio sales.  Since joining the company in 2004, he has incorporated media that now includes printed material such as product brochures and the long-running PEPNET newsletter, along with the company Website, social media, email and other outlets.  Additionally, he assists the staff with IT issues they encounter.  Bob has a background in graphic design, marketing, and advertising, in addition to project management and packaging.  He received his B.A. in Art from the University of Louisville, with additional post-graduate studies in education and design.